Compare Amgen, Inc. (AMGN) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Huntington Ingalls Industries Inc — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Huntington Ingalls Industries Inc trades at $284.93 (market cap $11.27B). The key difference: Amgen, Inc. is far larger — about 17.4× Huntington Ingalls Industries Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | HII | |
|---|---|---|
Market Cap | $196.12B | $11.27B |
Sector | Health | Technology |
52-Week High | $388.16 | $453.73 |
52-Week Low | $271.18 | $252.93 |
Enterprise Value | $241.41B | $13.99B |
Dividend Yield | 2.77% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HII trades at $286.09, down 0.04% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows stable profitability with a 4.71% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights ongoing naval contracts and shipbuilding milestones, supporting revenue visibility from its $54 billion backlog.
The stock presents a value opportunity with a P/E of 18.59 and P/S of 0.88 below industry averages, alongside a 44% analyst buy rating and a $384.50 price target implying significant upside. Risks include defense budget dependency and execution challenges, but strong cash flow and dividend payments bolster investor appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
